Hypofractionated IMRT With Temozolomide for HGG

Hypofractionated IMRT (VMAT-RA) With Temozolomide for Patients With Newly Diagnosed High Grade Glioma (HGG)

To evaluate safety and feasibility of hypofractionated IMRT in addition to chemotherapy, concomitant and adjuvant, in patients with newly diagnosed HGGs after surgery.

Primary endpoint: progression free survival (PFS), Overall Survival (OS) and Toxicity.

Secondary endpoint: to evaluate Quality of life (QoL) of patients after surgery, concomitant chemoradiotherapy and adjuvant chemotherapy through neuropsychological examination.

We designed a study of a hypofractionated intensity modulated radiation therapy (IMRT), using VMAT RapidArc approach. The potential advantage of this approach is to deliver a more selective irradiation to tumor's target with reducing dose to normal brain and to allow to deliver a higher dose, optimizing the therapeutic window

Inclusion Criteria:

• Age 18 to 70 years
• Karnosky performance status (KPS) ≥60
• Patients aged >70 years with KPS ≥80
• Histopathologically confirmed of HGG
• Estimated survival ≥ 3 months.
• Multifocal tumor
• Normal liver, Kidney and bone marrow function
• Written informed consent

Exclusion Criteria:

• Prior radiation therapy
• KPS ≤ 60
• Age > 70 years and KPS < 70
• Other primary cancer
• Pregnant women